Navigation Links
YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
Date:9/17/2009

or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Secures Committed Equity Financing Facility
4. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
5. Cell Biosciences Signs Agreement to Acquire Alpha Innotech
6. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
7. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
8. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
9. SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies
10. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
11. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research and ... Transfection Technology Market - Global Industry Analysis, Size, Share, ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... nucleic acids (either DNA or RNA) into cells. This ... of cancer cells and protein metabolism by affecting the ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... Role of Chairman of the Board - , , ... INSM ), a biopharmaceutical company, today announced that Geoffrey Allan, ... Chairman of the Board of Directors, effective immediately, due to ... President, Chief Executive Officer and Chairman of the Board since ...
... , , , PHILADELPHIA, June 15 ERT ... and eClinical technology, ePRO, and other services to the biopharmaceutical, medical ... its portfolio of products and services at Booth #507 at the ... , , ERT will be showcasing, for the first ...
... returns to Paris for 2010 when, with ICSE, PMEC and BioPh, the ... on Tuesday 5 - Thursday 7 October. This is a week earlier ... to the dates of the last staging in Paris ... the quartet of co-located events to rival the 25,000+ attendees expected this ...
Cached Biology Technology:Insmed CEO Resigns Due to Health Concerns 2Insmed CEO Resigns Due to Health Concerns 3ERT to Showcase Its Clinical Trials Portfolio at DIA's 45th Annual Meeting at Booth #507 2ERT to Showcase Its Clinical Trials Portfolio at DIA's 45th Annual Meeting at Booth #507 3Paris Dates for CPhI Worldwide 2010 2
(Date:7/14/2014)... protein, discovered in 2005, controls T-cell activation and ... In doing so, it helps to guarantee immunological ... own structures that can lead to autoimmune disease. ... affect between five and ten per cent of ... of complex environmental influences when a genetic predisposition ...
(Date:7/14/2014)... 140 years ago, Charles Darwin noticed something peculiar about ... are more tame, and they also tend to display ... patches of white fur, and more juvenile faces with ... pattern has proved elusive, but now, in a Perspectives ... new hypothesis has been proposed that could explain why ...
(Date:7/13/2014)... women suggests that experiencing one or more stressful events ... slow the body,s metabolism, potentially contributing to weight gain. ... stressors before giving them a meal consisting of 930 ... measured their metabolic rate how long it took ... took measures of blood sugar, triglycerides, insulin and the ...
Breaking Biology News(10 mins):Molecular mechanisms underlying the prevention of autoim-munity by Roquin revealed 2Domestication syndrome: White patches, baby faces and tameness 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 4
... Florida State University marine biologist David L. Kimbro will ... in a massive effort to study the health and ... estuaries spanning 1,000 miles of Atlantic and Gulf of ... June 1, has become even more vital now following ...
... fluent in English whose first language is Chinese retrieve their ... in the June 2 issue of The Journal of ... second language in adolescence or later recall the sounds of ... study, Yan Jing Wu, PhD, and Guillaume Thierry, PhD, of ...
... release is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-06/sfeb-tio060110.php,">Chinese . ... of Medicine, in New Orleans, LA, have demonstrated ... seed oil ( Nigella sativa ) can suppress ... cell lines, in vitro. Although previous studies ...
Cached Biology News:Oil spill reshapes sweeping new study of oyster reefs -- Virginia to Florida 2Oil spill reshapes sweeping new study of oyster reefs -- Virginia to Florida 3Oil spill reshapes sweeping new study of oyster reefs -- Virginia to Florida 4Second language learners recall native language when reading 2Thymoquinone induced oxidative stress targets highly aggressive prostate cancers 2